OTC education efforts for Questran would stress physician consultation, BMS says.
This article was originally published in The Tan Sheet
OTC QUESTRAN AD CAMPAIGN WOULD STRESS PHYSICIAN CONSULTATION as part of a three-step approach to cholesterol lowering, Bristol-Myers Products President Sion Boney reported during a May 13 meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees to consider the Rx-to-OTC switch of Questran (cholestyramine). "Everything that we [will] say in advertising has a clear message: consult your physician first -- that is the most important step," Boney emphasized.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC